25 XP   0   0   10

Phathom Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Phathom Pharmaceuticals Inc together

PenkeI guess you are interested in Phathom Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Phathom Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Phathom Pharmaceuticals Inc

I send you an email if I find something interesting about Phathom Pharmaceuticals Inc.

Quick analysis of Phathom Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Phathom Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-1.24
Expected worth in 1 year
$-1.21
How sure are you?
13.6%

+ What do you gain per year?

Total Gains per Share
$0.04
Return On Investment
0.4%

For what price can you sell your share?

Current Price per Share
$9.06
Expected price per share
$6.095 - $12.65
How sure are you?
50%

1. Valuation of Phathom Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$9.06

Intrinsic Value Per Share

$-31.39 - $-36.73

Total Value Per Share

$-32.63 - $-37.97

2. Growth of Phathom Pharmaceuticals Inc (5 min.)




Is Phathom Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$72.7m-$17.5m-$23.2m-57.0%

How much money is Phathom Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$50.3m-$55.7m$5.3m10.7%
Net Profit Margin-2,916.8%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Phathom Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#989 / 1010

Most Revenue
#605 / 1010

Most Profit
#890 / 1010

Most Efficient
#871 / 1010

What can you expect buying and holding a share of Phathom Pharmaceuticals Inc? (5 min.)

Welcome investor! Phathom Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Phathom Pharmaceuticals Inc.

What can you expect buying and holding a share of Phathom Pharmaceuticals Inc?

First you should know what it really means to hold a share of Phathom Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Phathom Pharmaceuticals Inc is $9.06. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Phathom Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Phathom Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-1.24. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.63 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Phathom Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.36-15.0%-0.86-9.5%-0.85-9.3%-0.78-8.6%-0.71-7.8%
Usd Book Value Change Per Share-0.94-10.4%0.010.1%-0.63-6.9%-0.06-0.7%-0.06-0.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.94-10.4%0.010.1%-0.63-6.9%-0.06-0.7%-0.06-0.6%
Usd Price Per Share9.13-10.24-11.09-18.41-16.74-
Price to Earnings Ratio-1.68--3.26--3.37--7.38--6.71-
Price-to-Total Gains Ratio-9.71--11.56--20.30--32.28--32.28-
Price to Book Ratio-7.34-0.37--20.72-1.51-1.37-
Price-to-Total Gains Ratio-9.71--11.56--20.30--32.28--32.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.06
Number of shares110
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.01-0.06
Usd Total Gains Per Share0.01-0.06
Gains per Quarter (110 shares)0.97-6.72
Gains per Year (110 shares)3.87-26.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
104-60-27-37
208-20-54-64
301220-81-91
401560-108-118
5019100-134-145
6023140-161-172
7027180-188-199
8031220-215-226
9035260-242-253
10039300-269-280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.022.00.00.0%0.022.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.016.01.015.0%3.017.02.013.6%3.017.02.013.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.016.01.015.0%3.017.02.013.6%3.017.02.013.6%

Fundamentals of Phathom Pharmaceuticals Inc

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Fundamental data was last updated by Penke on 2024-04-12 15:02:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Phathom Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Phathom Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Phathom Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -11,667.2% means that $-116.67 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Phathom Pharmaceuticals Inc:

  • The MRQ is -11,667.2%. The company is making a huge loss. -2
  • The TTM is -2,916.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-11,667.2%TTM-2,916.8%-8,750.4%
TTM-2,916.8%YOY--2,916.8%
TTM-2,916.8%5Y-583.4%-2,333.4%
5Y-583.4%10Y-530.3%-53.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11,667.2%-200.1%-11,467.1%
TTM-2,916.8%-216.8%-2,700.0%
YOY--288.3%+288.3%
5Y-583.4%-449.1%-134.3%
10Y-530.3%-605.5%+75.2%
1.1.2. Return on Assets

Shows how efficient Phathom Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Phathom Pharmaceuticals Inc to the Biotechnology industry mean.
  • -19.2% Return on Assets means that Phathom Pharmaceuticals Inc generated $-0.19 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Phathom Pharmaceuticals Inc:

  • The MRQ is -19.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -19.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.2%TTM-19.8%+0.5%
TTM-19.8%YOY-30.9%+11.1%
TTM-19.8%5Y-27.3%+7.5%
5Y-27.3%10Y-28.7%+1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.2%-13.3%-5.9%
TTM-19.8%-12.8%-7.0%
YOY-30.9%-11.7%-19.2%
5Y-27.3%-13.9%-13.4%
10Y-28.7%-15.7%-13.0%
1.1.3. Return on Equity

Shows how efficient Phathom Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Phathom Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means Phathom Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Phathom Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-58.2%+58.2%
TTM-58.2%YOY-28.5%-29.6%
TTM-58.2%5Y-29.7%-28.5%
5Y-29.7%10Y-27.0%-2.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.9%+16.9%
TTM-58.2%-16.1%-42.1%
YOY-28.5%-15.1%-13.4%
5Y-29.7%-19.3%-10.4%
10Y-27.0%-20.2%-6.8%

1.2. Operating Efficiency of Phathom Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Phathom Pharmaceuticals Inc is operating .

  • Measures how much profit Phathom Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Phathom Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -9,756.7% means the company generated $-97.57  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Phathom Pharmaceuticals Inc:

  • The MRQ is -9,756.7%. The company is operating very inefficient. -2
  • The TTM is -2,439.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-9,756.7%TTM-2,439.2%-7,317.6%
TTM-2,439.2%YOY--2,439.2%
TTM-2,439.2%5Y-487.8%-1,951.3%
5Y-487.8%10Y-443.5%-44.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9,756.7%-296.2%-9,460.5%
TTM-2,439.2%-232.5%-2,206.7%
YOY--298.2%+298.2%
5Y-487.8%-492.1%+4.3%
10Y-443.5%-632.4%+188.9%
1.2.2. Operating Ratio

Measures how efficient Phathom Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 102.88 means that the operating costs are $102.88 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Phathom Pharmaceuticals Inc:

  • The MRQ is 102.884. The company is inefficient in keeping operating costs low. -1
  • The TTM is 25.721. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ102.884TTM25.721+77.163
TTM25.721YOY-+25.721
TTM25.7215Y5.144+20.577
5Y5.14410Y4.677+0.468
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ102.8843.231+99.653
TTM25.7213.310+22.411
YOY-3.890-3.890
5Y5.1445.739-0.595
10Y4.6777.876-3.199

1.3. Liquidity of Phathom Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Phathom Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 10.25 means the company has $10.25 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Phathom Pharmaceuticals Inc:

  • The MRQ is 10.248. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.337. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ10.248TTM10.337-0.089
TTM10.337YOY9.360+0.977
TTM10.3375Y13.360-3.023
5Y13.36010Y12.183+1.177
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.2483.890+6.358
TTM10.3374.173+6.164
YOY9.3605.344+4.016
5Y13.3606.126+7.234
10Y12.1836.448+5.735
1.3.2. Quick Ratio

Measures if Phathom Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Phathom Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 9.88 means the company can pay off $9.88 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Phathom Pharmaceuticals Inc:

  • The MRQ is 9.877. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.827. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.877TTM9.827+0.049
TTM9.827YOY9.121+0.706
TTM9.8275Y12.937-3.110
5Y12.93710Y11.780+1.158
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.8773.514+6.363
TTM9.8273.998+5.829
YOY9.1215.380+3.741
5Y12.9376.105+6.832
10Y11.7806.404+5.376

1.4. Solvency of Phathom Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Phathom Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Phathom Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.18 means that Phathom Pharmaceuticals Inc assets are financed with 117.6% credit (debt) and the remaining percentage (100% - 117.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Phathom Pharmaceuticals Inc:

  • The MRQ is 1.176. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.203. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.176TTM1.203-0.027
TTM1.203YOY1.091+0.112
TTM1.2035Y0.960+0.243
5Y0.96010Y1.093-0.133
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1760.339+0.837
TTM1.2030.336+0.867
YOY1.0910.271+0.820
5Y0.9600.366+0.594
10Y1.0930.389+0.704
1.4.2. Debt to Equity Ratio

Measures if Phathom Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Phathom Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Phathom Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.515-3.515
TTM3.515YOY0.730+2.785
TTM3.5155Y1.133+2.382
5Y1.13310Y1.030+0.103
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.388-0.388
TTM3.5150.402+3.113
YOY0.7300.335+0.395
5Y1.1330.426+0.707
10Y1.0300.461+0.569

2. Market Valuation of Phathom Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Phathom Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Phathom Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -1.68 means the investor is paying $-1.68 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Phathom Pharmaceuticals Inc:

  • The EOD is -1.665. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.677. Based on the earnings, the company is expensive. -2
  • The TTM is -3.264. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.665MRQ-1.677+0.013
MRQ-1.677TTM-3.264+1.586
TTM-3.264YOY-3.367+0.103
TTM-3.2645Y-7.380+4.116
5Y-7.38010Y-6.709-0.671
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.665-2.264+0.599
MRQ-1.677-2.629+0.952
TTM-3.264-2.680-0.584
YOY-3.367-4.145+0.778
5Y-7.380-6.257-1.123
10Y-6.709-6.254-0.455
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Phathom Pharmaceuticals Inc:

  • The EOD is -2.992. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.015. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.919. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.992MRQ-3.015+0.023
MRQ-3.015TTM-4.919+1.904
TTM-4.919YOY-4.431-0.488
TTM-4.9195Y-11.672+6.753
5Y-11.67210Y-10.611-1.061
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.992-2.973-0.019
MRQ-3.015-3.333+0.318
TTM-4.919-3.553-1.366
YOY-4.431-5.605+1.174
5Y-11.672-8.376-3.296
10Y-10.611-8.865-1.746
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Phathom Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -7.34 means the investor is paying $-7.34 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Phathom Pharmaceuticals Inc:

  • The EOD is -7.282. Based on the equity, the company is expensive. -2
  • The MRQ is -7.338. Based on the equity, the company is expensive. -2
  • The TTM is 0.373. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-7.282MRQ-7.338+0.056
MRQ-7.338TTM0.373-7.711
TTM0.373YOY-20.718+21.092
TTM0.3735Y1.510-1.137
5Y1.51010Y1.372+0.137
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.2821.896-9.178
MRQ-7.3382.115-9.453
TTM0.3732.093-1.720
YOY-20.7182.884-23.602
5Y1.5103.542-2.032
10Y1.3723.916-2.544
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Phathom Pharmaceuticals Inc.

3.1. Institutions holding Phathom Pharmaceuticals Inc

Institutions are holding 87.91% of the shares of Phathom Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Medicxi Ventures Management (Jersey) Ltd6.487611.5912376086900
2023-12-31The Carlyle Group Inc6.03211.5355349680800
2023-12-31Amvescap Plc.5.46430.00693167653-251306-7.3504
2023-12-31BlackRock Inc4.62120.000626788912411499.8923
2023-12-31Ensign Peak Advisors Inc3.93310.0412228000054782831.6267
2023-12-31NEA Management Company, LLC3.38131.1927196016968357453.5467
2023-12-31Vanguard Group Inc3.37490.00041956429337671.7563
2023-12-31Avidity Partners Management LP2.96980.572817215801042806.4478
2023-12-31Gilder Gagnon Howe & CO LLC2.51010.1823145513214508411.0747
2023-12-31683 Capital Management LLC2.2080.9572128000018000016.3636
2023-12-31Woodline Partners LP1.89080.1088109612135610048.1203
2023-12-31Decheng Capital LLC1.46632.16828500008500000
2023-12-31Geode Capital Management, LLC1.26840.0007735273527037.7213
2023-12-31Catalys Pacific LLC1.24546.17917219627219620
2023-12-31State Street Corporation1.18650.0003687837202413.0319
2023-12-31Newtyn Management LLC1.11571.159264676014676029.352
2023-12-31Kennedy Capital Management Inc0.98670.1141571976-489769-46.1287
2023-12-31GW&K Investment Management, LLC0.96860.0478561490-15960-2.7639
2023-12-31Propel Bio Management LLC0.76433.35374430474430470
2023-12-31StepStone Group LLC0.72810.693642208500
Total 52.603229.906330494082+3769460+12.4%

3.2. Funds holding Phathom Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Invesco OFI Global Equity2.99060.17661733665-11709-0.6709
2024-02-29Invesco Global A2.99060.1954173366500
2024-02-29Vanguard Total Stock Mkt Idx Inv1.91210.0008110845200
2024-03-31Jennison Health Sciences Equity1.53920.51368922708922700
2024-03-28iShares Russell 2000 ETF1.34990.01277825383780.0483
2024-02-29Simplify Propel Opportunities ETF0.90214.7962522935285000119.7806
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.88790.0054514691-1016-0.197
2023-11-30MEDICAL BioHealth EUR Acc0.75370.48664369434200010.6344
2024-02-29PGIM Jennison Health Sciences Z0.72010.24874174224174220
2024-02-29Invesco VI Global I0.67920.19439371700
2024-02-29Allspring (Lux) WW Glb L/SEq IPUSD Acc0.61250.283935508915411776.6858
2024-01-31Fidelity Small Cap Index0.55420.008732128737781.1899
2023-12-31JNL/Invesco Global Growth A0.55220.174332013000
2024-01-31Strategic Advisers Small-Mid Cap0.39540.017222921300
2024-03-28iShares Russell 2000 Value ETF0.39090.0192226624-144-0.0635
2023-12-31BrighthouseI Invesco Global Equity A0.37920.1752219817-455-0.2066
2024-02-29APO Medical Opportunities R0.37360.270621660000
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.34230.005119844434001.7432
2024-03-28iShares Biotechnology ETF0.32920.0266190850-6927-3.5024
2024-02-29Fidelity Extended Market Index0.32360.0052187575-909-0.4823
Total 18.97857.61611001927+1777205+16.2%

3.3. Insider Transactions

Insiders are holding 10.463% of the shares of Phathom Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-08Molly HendersonSELL343511.1
2024-03-22Terrie CurranSELL168519.11
2024-01-24Pharmaceutical Co Ltd TakedaSELL37037038.1
2024-01-19Molly HendersonSELL63077.75
2023-11-08Asit ParikhBUY25007.8
2023-11-06Asit ParikhBUY10008.04
2023-11-01Molly HendersonSELL124928.88
2023-06-02Molly HendersonSELL196011.41
2023-05-22Molly HendersonSELL211012.87
2023-04-11Azmi NabulsiBUY100008.26

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Phathom Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.9400.009-10803%-0.628-33%-0.061-94%-0.057-94%
Book Value Per Share---1.244-0.697-44%-0.300-76%0.764-263%0.692-280%
Current Ratio--10.24810.337-1%9.360+9%13.360-23%12.183-16%
Debt To Asset Ratio--1.1761.203-2%1.091+8%0.960+22%1.093+8%
Debt To Equity Ratio---3.515-100%0.730-100%1.133-100%1.030-100%
Dividend Per Share----0%-0%-0%-0%
Eps---1.361-0.862-37%-0.845-38%-0.776-43%-0.706-48%
Free Cash Flow Per Share---0.757-0.595-21%-0.631-17%-0.464-39%-0.423-44%
Free Cash Flow To Equity Per Share--2.8680.976+194%0.895+220%0.650+342%0.591+385%
Gross Profit Margin--1.0491.012+4%1.000+5%1.002+5%1.002+5%
Intrinsic Value_10Y_max---36.727--------
Intrinsic Value_10Y_min---31.388--------
Intrinsic Value_1Y_max---2.661--------
Intrinsic Value_1Y_min---2.613--------
Intrinsic Value_3Y_max---8.771--------
Intrinsic Value_3Y_min---8.358--------
Intrinsic Value_5Y_max---15.819--------
Intrinsic Value_5Y_min---14.616--------
Market Cap529805244.000-1%533898662.000598808576.000-11%648368172.500-18%1076715127.500-50%978831934.091-45%
Net Profit Margin---116.672-29.168-75%--100%-5.834-95%-5.303-95%
Operating Margin---97.567-24.392-75%--100%-4.878-95%-4.435-95%
Operating Ratio--102.88425.721+300%-+100%5.144+1900%4.677+2100%
Pb Ratio-7.282+1%-7.3380.373-2067%-20.718+182%1.510-586%1.372-635%
Pe Ratio-1.665+1%-1.677-3.264+95%-3.367+101%-7.380+340%-6.709+300%
Price Per Share9.060-1%9.13010.240-11%11.088-18%18.413-50%16.739-45%
Price To Free Cash Flow Ratio-2.992+1%-3.015-4.919+63%-4.431+47%-11.672+287%-10.611+252%
Price To Total Gains Ratio-9.635+1%-9.710-11.558+19%-20.300+109%-32.277+232%-32.277+232%
Quick Ratio--9.8779.827+1%9.121+8%12.937-24%11.780-16%
Return On Assets---0.192-0.198+3%-0.309+61%-0.273+42%-0.287+49%
Return On Equity----0.5820%-0.2850%-0.2970%-0.2700%
Total Gains Per Share---0.9400.009-10803%-0.628-33%-0.061-94%-0.057-94%
Usd Book Value---72759000.000-40781750.000-44%-17550500.000-76%44663800.000-263%40486545.455-280%
Usd Book Value Change Per Share---0.9400.009-10803%-0.628-33%-0.061-94%-0.057-94%
Usd Book Value Per Share---1.244-0.697-44%-0.300-76%0.764-263%0.692-280%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.361-0.862-37%-0.845-38%-0.776-43%-0.706-48%
Usd Free Cash Flow---44272000.000-34803500.000-21%-36892750.000-17%-27155000.000-39%-24712318.182-44%
Usd Free Cash Flow Per Share---0.757-0.595-21%-0.631-17%-0.464-39%-0.423-44%
Usd Free Cash Flow To Equity Per Share--2.8680.976+194%0.895+220%0.650+342%0.591+385%
Usd Market Cap529805244.000-1%533898662.000598808576.000-11%648368172.500-18%1076715127.500-50%978831934.091-45%
Usd Price Per Share9.060-1%9.13010.240-11%11.088-18%18.413-50%16.739-45%
Usd Profit---79570000.000-50361500.000-37%-55751500.000-30%-47626700.000-40%-43332181.818-46%
Usd Revenue--682000.000170500.000+300%-+100%34100.000+1900%31000.000+2100%
Usd Total Gains Per Share---0.9400.009-10803%-0.628-33%-0.061-94%-0.057-94%
 EOD+2 -6MRQTTM+11 -22YOY+10 -235Y+9 -2410Y+9 -24

4.2. Fundamental Score

Let's check the fundamental score of Phathom Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.665
Price to Book Ratio (EOD)Between0-1-7.282
Net Profit Margin (MRQ)Greater than0-116.672
Operating Margin (MRQ)Greater than0-97.567
Quick Ratio (MRQ)Greater than19.877
Current Ratio (MRQ)Greater than110.248
Debt to Asset Ratio (MRQ)Less than11.176
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.192
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Phathom Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.671
Ma 20Greater thanMa 5010.310
Ma 50Greater thanMa 1009.611
Ma 100Greater thanMa 2008.778
OpenGreater thanClose9.010
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  -16822-14623-1232-1211,026905
Cost of Revenue  168-22146-23123-2121-344-223



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets413,842
Total Liabilities486,601
Total Stockholder Equity-72,759
 As reported
Total Liabilities 486,601
Total Stockholder Equity+ -72,759
Total Assets = 413,842

Assets

Total Assets413,842
Total Current Assets397,432
Long-term Assets16,410
Total Current Assets
Cash And Cash Equivalents 381,393
Net Receivables 1,637
Inventory 1,208
Other Current Assets 13,194
Total Current Assets  (as reported)397,432
Total Current Assets  (calculated)397,432
+/-0
Long-term Assets
Property Plant Equipment 3,621
Long-term Assets Other 9,926
Long-term Assets  (as reported)16,410
Long-term Assets  (calculated)13,547
+/- 2,863

Liabilities & Shareholders' Equity

Total Current Liabilities38,781
Long-term Liabilities447,820
Total Stockholder Equity-72,759
Total Current Liabilities
Short-term Debt 726
Accounts payable 12,601
Other Current Liabilities 7,111
Total Current Liabilities  (as reported)38,781
Total Current Liabilities  (calculated)20,438
+/- 18,343
Long-term Liabilities
Long term Debt 137,842
Capital Lease Obligations Min Short Term Debt462
Long-term Liabilities Other 309,516
Long-term Liabilities  (as reported)447,820
Long-term Liabilities  (calculated)447,820
+/-0
Total Stockholder Equity
Common Stock5
Retained Earnings -928,685
Other Stockholders Equity 855,921
Total Stockholder Equity (as reported)-72,759
Total Stockholder Equity (calculated)-72,759
+/-0
Other
Capital Stock5
Cash and Short Term Investments 381,393
Common Stock Shares Outstanding 51,289
Current Deferred Revenue18,343
Liabilities and Stockholders Equity 413,842
Net Debt -242,363
Net Invested Capital 65,083
Net Working Capital 358,651
Property Plant and Equipment Gross 5,667
Short Long Term Debt Total 139,030



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
> Total Assets 
902
902
84,879
84,879
79,706
257,178
263,915
252,422
230,889
295,111
246,363
214,579
228,377
189,431
149,049
213,502
201,931
164,810
144,010
265,039
236,992
413,842
413,842236,992265,039144,010164,810201,931213,502149,049189,431228,377214,579246,363295,111230,889252,422263,915257,17879,70684,87984,879902902
   > Total Current Assets 
902
902
84,542
84,542
77,653
255,601
261,827
248,679
227,161
291,368
242,810
211,338
225,313
186,526
145,741
209,257
196,838
160,512
139,843
257,718
226,726
397,432
397,432226,726257,718139,843160,512196,838209,257145,741186,526225,313211,338242,810291,368227,161248,679261,827255,60177,65384,54284,542902902
       Cash And Cash Equivalents 
879
879
82,917
82,917
74,484
243,765
256,672
247,271
226,361
287,496
237,974
209,669
224,618
183,259
138,090
207,392
196,838
155,385
129,574
248,847
213,677
381,393
381,393213,677248,847129,574155,385196,838207,392138,090183,259224,618209,669237,974287,496226,361247,271256,672243,76574,48482,91782,917879879
       Net Receivables 
0
0
0
0
0
0
0
0
0
82
0
0
0
0
0
0
0
0
0
0
0
1,637
1,6370000000000082000000000
       Other Current Assets 
0
23
0
1,625
3,169
11,836
5,155
1,408
800
3,872
4,836
1,669
695
3,267
7,651
1,865
975
5,127
10,269
8,760
12,938
13,194
13,19412,9388,76010,2695,1279751,8657,6513,2676951,6694,8363,8728001,4085,15511,8363,1691,6250230
   > Long-term Assets 
0
0
0
337
2,053
1,577
2,088
3,743
3,728
3,743
3,553
3,241
3,064
2,905
3,308
4,245
5,093
4,298
4,167
7,321
10,266
16,410
16,41010,2667,3214,1674,2985,0934,2453,3082,9053,0643,2413,5533,7433,7283,7432,0881,5772,053337000
       Property Plant Equipment 
0
0
0
0
40
1,396
1,707
3,362
3,347
3,359
3,168
2,950
2,723
2,564
2,503
3,440
3,313
3,494
3,363
3,044
3,658
3,621
3,6213,6583,0443,3633,4943,3133,4402,5032,5642,7232,9503,1683,3593,3473,3621,7071,396400000
       Other Assets 
0
0
337
337
2,013
181
381
381
381
2,757
385
291
341
341
805
213,502
0
804
0
0
0
0
00008040213,5028053413412913852,7573813813811812,01333733700
> Total Liabilities 
2,188
2,188
169,264
169,264
232,167
29,223
55,220
63,999
74,501
100,840
82,024
82,451
124,896
117,275
111,014
220,502
228,354
239,624
234,205
247,439
254,765
486,601
486,601254,765247,439234,205239,624228,354220,502111,014117,275124,89682,45182,024100,84074,50163,99955,22029,223232,167169,264169,2642,1882,188
   > Total Current Liabilities 
2,188
2,188
144,752
144,752
207,493
3,748
4,576
13,258
27,670
55,524
40,845
39,611
27,811
18,921
11,394
21,075
22,879
26,237
14,443
21,545
23,979
38,781
38,78123,97921,54514,44326,23722,87921,07511,39418,92127,81139,61140,84555,52427,67013,2584,5763,748207,493144,752144,7522,1882,188
       Short-term Debt 
0
1,950
0
92,743
95,229
161
148
1,805
5,987
7,827
12,242
10,825
484
487
490
628
685
708
712
717
721
726
72672171771270868562849048748410,82512,2427,8275,9871,80514816195,22992,74301,9500
       Short Long Term Debt 
0
0
0
92,743
95,229
0
0
1,389
5,556
7,353
11,765
10,345
0
0
0
0
0
0
0
0
0
0
000000000010,34511,7657,3535,5561,3890095,22992,743000
       Accounts payable 
55
55
450
450
439
699
1,187
4,894
4,788
16,782
10,857
5,401
5,582
5,150
2,776
5,689
7,055
9,997
4,727
4,147
5,767
12,601
12,6015,7674,1474,7279,9977,0555,6892,7765,1505,5825,40110,85716,7824,7884,8941,1876994394504505555
       Other Current Liabilities 
0
183
49,597
51,559
111,825
2,888
3,241
6,559
16,895
30,915
17,746
23,385
21,745
13,284
8,128
14,758
15,139
15,532
9,004
276
2,391
7,111
7,1112,3912769,00415,53215,13914,7588,12813,28421,74523,38517,74630,91516,8956,5593,2412,888111,82551,55949,5971830
   > Long-term Liabilities 
0
0
0
24,512
24,674
25,475
50,644
50,741
46,831
45,316
41,179
42,840
97,085
98,354
99,620
199,427
205,475
213,387
219,762
225,894
230,786
447,820
447,820230,786225,894219,762213,387205,475199,42799,62098,35497,08542,84041,17945,31646,83150,74150,64425,47524,67424,512000
       Long term Debt Total 
0
0
0
22,449
22,611
22,777
45,913
0
0
39,634
35,587
0
0
89,671
91,037
92,432
93,878
0
96,638
0
0
0
00096,638093,87892,43291,03789,6710035,58739,6340045,91322,77722,61122,449000
       Other Liabilities 
0
0
2,063
2,063
2,063
2,063
4,125
4,125
4,125
4,125
4,125
4,125
7,500
7,500
7,500
220,502
7,500
7,500
0
7,500
0
0
007,50007,5007,500220,5027,5007,5007,5004,1254,1254,1254,1254,1254,1252,0632,0632,0632,06300
       Deferred Long Term Liability 
0
0
300
300
2,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000002,00030030000
> Total Stockholder Equity
-1,286
-1,286
-84,385
-84,385
-152,461
227,955
208,695
188,423
156,388
194,271
164,339
132,128
103,481
72,156
38,035
-7,000
-26,423
-74,814
-90,195
17,600
-17,773
-72,759
-72,759-17,77317,600-90,195-74,814-26,423-7,00038,03572,156103,481132,128164,339194,271156,388188,423208,695227,955-152,461-84,385-84,385-1,286-1,286
   Common Stock
0
0
0
0
0
2
2
3
3
3
3
3
3
3
3
3
3
3
4
5
5
5
5554333333333332200000
   Retained Earnings -928,685-849,115-805,872-764,907-727,093-672,046-620,955-570,035-529,370-493,544-456,882-420,330-385,487-331,766-297,661-276,560-256,419-158,413-90,301-90,301-1,288-1,288
   Capital Surplus 
0
0
0
5,916
5,952
484,372
485,253
0
0
579,755
584,666
0
0
601,523
608,067
613,952
645,620
0
674,708
0
0
0
000674,7080645,620613,952608,067601,52300584,666579,75500485,253484,3725,9525,916000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
2
0
5,916
5,952
484,372
485,253
486,081
488,151
579,755
584,666
589,007
597,022
601,523
608,067
613,952
645,620
652,276
674,708
823,467
831,337
855,921
855,921831,337823,467674,708652,276645,620613,952608,067601,523597,022589,007584,666579,755488,151486,081485,253484,3725,9525,916020



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue682
Cost of Revenue-167
Gross Profit515515
 
Operating Income (+$)
Gross Profit515
Operating Expense-167,827
Operating Income-167,312-167,312
 
Operating Expense (+$)
Research Development49,899
Selling General Administrative117,928
Selling And Marketing Expenses0
Operating Expense167,827167,827
 
Net Interest Income (+$)
Interest Income7,876
Interest Expense-41,968
Other Finance Cost-0
Net Interest Income-34,092
 
Pretax Income (+$)
Operating Income-167,312
Net Interest Income-34,092
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-201,592-167,124
EBIT - interestExpense = -201,592
-159,812
-159,624
Interest Expense41,968
Earnings Before Interest and Taxes (EBIT)-159,624-159,624
Earnings Before Interest and Taxes (EBITDA)-159,049
 
After tax Income (+$)
Income Before Tax-201,592
Tax Provision-0
Net Income From Continuing Ops-201,592-201,592
Net Income-201,592
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses167,994
Total Other Income/Expenses Net-18834,092
 

Technical Analysis of Phathom Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Phathom Pharmaceuticals Inc. The general trend of Phathom Pharmaceuticals Inc is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Phathom Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Phathom Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.55 < 12.27 < 12.65.

The bearish price targets are: 7.55 > 7.28 > 6.095.

Tweet this
Phathom Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Phathom Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Phathom Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Phathom Pharmaceuticals Inc. The current macd is -0.09578254.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Phathom Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Phathom Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Phathom Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Phathom Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartPhathom Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Phathom Pharmaceuticals Inc. The current adx is 20.92.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Phathom Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Phathom Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Phathom Pharmaceuticals Inc. The current sar is 11.28.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Phathom Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Phathom Pharmaceuticals Inc. The current rsi is 41.67. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Phathom Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartPhathom Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Phathom Pharmaceuticals Inc. The current phase is Oversold in neutral market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Phathom Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Phathom Pharmaceuticals Inc Daily Stochastic Oscillator ChartPhathom Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Phathom Pharmaceuticals Inc. The current cci is -129.82858747.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Phathom Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartPhathom Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Phathom Pharmaceuticals Inc. The current cmo is -30.56263809.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Phathom Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartPhathom Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Phathom Pharmaceuticals Inc. The current willr is -93.31395349.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Phathom Pharmaceuticals Inc Daily Williams %R ChartPhathom Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Phathom Pharmaceuticals Inc. The current atr is 0.77122544.

Phathom Pharmaceuticals Inc Daily Average True Range (ATR) ChartPhathom Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Phathom Pharmaceuticals Inc. The current obv is 2,514,997.

Phathom Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartPhathom Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Phathom Pharmaceuticals Inc. The current mfi is 49.30.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Phathom Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartPhathom Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Phathom Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-15WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Phathom Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Phathom Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.671
Ma 20Greater thanMa 5010.310
Ma 50Greater thanMa 1009.611
Ma 100Greater thanMa 2008.778
OpenGreater thanClose9.010
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Phathom Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Phathom Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Phathom Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Phathom Pharmaceuticals Inc

I send you an email if I find something interesting about Phathom Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Phathom Pharmaceuticals Inc.

Receive notifications about Phathom Pharmaceuticals Inc in your mailbox!